Consequently, the patient was diagnosed as having BM involvement of AITL and plasma cell leukemia (IgMκ) simultaneously. Following initial diagnosis, the patient received the first cycle of chemotherapy consisting of vincristine, doxorubicin, cyclophosphamide, and prednisolone. The patient also suffered from respiratory failure combined with septic shock and was managed at the intensive care unit. Following discharge, the patient was followed up to monitor the disease in an outpatient clinic, without further chemotherapy.
AITL, one subtype of peripheral T-cell lymphoma, is frequently associated with polyclonal B-cell or plasma cell proliferation [1] . The B-cell expansion observed in AITL has been proposed to be related to the functions of neoplastic follicular helper T-cells. However, proliferation of clonal B-cells or plasma cells has rarely been reported [2] [3] [4] . We hypothesized that the clonal plasma cell population is unrelated to the patient's AITL status. In over 20% of clonal plasma cells in PB and BM, the presence of M-protein in serum and absence of EBV could support this possibility. Factors contradicting plasma cell neoplasm include the followings: negative organ impairment including hypercalcemia; renal insufficiency; anemia; bone lesions; and IgM paraprotein (non-IgG or IgA) that could be associated with a clone of lymphoplasmacytic cells [5] . However, there was no evidence of CD20 + neoplastic Bcells in BM.
In conclusion, the current case emphasizes that AITL could present with marked proliferation of clonal plasma cells, thereby potentially masking underlying T-cell lymphoma. Being aware of this possible effect is clinically important when determining treatment strategies and prognostic stratification, especially in the patients with a clonal B-cell population. 
